Biotech Values

[alertmeipp]

>> I am somewhat concerned about what Amphastar’s approval means vis-à-vis MNTA’s proprietary technology.

I agree - but we are not paying much for the technology. I think we will see more from the forthcoming suit.

But at minimum, there are still competitive advantage to the technology.

The good thing today is that the big uncertainty is now removed and we can wait for mC and FOB to come.